Private payer-negotiated prices for FDA-approved biologic treatments for allergic diseases.
Annette A Wang, Vinay K Rathi, Roy Xiao, Eric H Holbrook, George A Scangas, Alan D Workman, Stacey T Gray
Author Information
- Annette A Wang: Harvard Medical School, Boston, Massachusetts, USA.
- Vinay K Rathi: Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
- Roy Xiao: Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
- Eric H Holbrook: Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, Massachusetts, USA. ORCID
- George A Scangas: Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
- Alan D Workman: Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
- Stacey T Gray: Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
No abstract text available.
- Wu AC, Fuhlbrigge AL, Robayo MA, Shaker M. Cost-effectiveness of biologics for allergic diseases. J Allergy Clin Immunol Pract. 2021;9(3):1107-1117.e2.
- Follow the Dollar Part II. PhRMA. Accessed September 10, 2021. https://www.phrma.org/resource-center/Topics/Cost-and-Value/Follow-the-Dollar-Part-2
- Shaughnessy AF. Monoclonal antibodies: magic bullets with a hefty price tag. BMJ. 2012;345:e8346.
- Robinson JC, Whaley CM, Brown TT. Price differences to insurers for infused cancer drugs in hospital outpatient departments and physician offices. Health Aff Proj Hope. 2021;40(9):1395-1401. https://doi.org/10.1377/hlthaff.2021.00211
- Medicare and Medicaid Programs: CY 2020 Hospital Outpatient PPS Policy Changes and Payment Rates and Ambulatory Surgical Center Payment System Policy Changes and Payment Rates. Price Transparency Requirements for Hospitals To Make Standard Charges Public. Centers for Medicare and Medicaid Services. https://www.govinfo.gov/content/pkg/FR-2019-11-27/pdf/2019-24931.pdf
- Xiao R, Rathi VK, Gross CP, Ross JS, Sethi RKV. Payer-negotiated prices in the diagnosis and management of thyroid cancer in 2021. JAMA. 2021;326(2):184-185.
- 2021 ASP Drug Pricing Files | CMS. Accessed September 21, 2021. https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2021-asp-drug-pricing-files
- Richman B, Hall M, Schulman K. The no surprises act and informed financial consent. N Engl J Med. 2021;385(15):1348-1351.
- Review (ICER). Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks 2018. https://icer.org/wp-content/uploads/2020/10/Asthma-Revised-Report-FOR-PUBLICATION-11.13.2018.pdf
- Scangas GA, Wu AW, Ting JY, et al. Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. The Laryngoscope. 2021;131(1):E26-E33. https://doi.org/10.1002/lary.28648
Biological Products
Humans
Hypersensitivity
